Skip to main content

Advertisement

Springer Nature Link
Log in

Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome

  • Case Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may be refractory to multiple systemic treatments. These cases can be difficult to achieve and maintain complete response and there is a need for novel therapeutics. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway by Tenalisib presents one such emerging drug. We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hristov AC, Tejasvi T, A Wilcox R (2021) Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 96(10):1313–1328. https://doi.org/10.1002/ajh.26299

  2. Alpdogan O, Kartan S, Johnson W, Sokol K, Porcu P (2019) Systemic therapy of cutaneous T-cell lymphoma (CTCL). Chin Clin Oncol 8(1):10. https://doi.org/10.21037/cco.2019.01.02

    Article  PubMed  Google Scholar 

  3. Lampson BL, Brown JR (2017) PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 26(11):1267–1279. https://doi.org/10.1080/13543784.2017.1384815

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Huen A, Haverkos BM, Zain J et al (2020) Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel) 12(8):2293. Published 2020 Aug 15. https://doi.org/10.3390/cancers12082293

  5. Horwitz SM, Koch R, Porcu P et al (2018) Activity of the PI3K-δ, γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 131(8):888–898. https://doi.org/10.1182/blood-2017-08-802470

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Safety and Efficacy of Tenalisib (RP6530) in Combination with Romidepsin in Patients with Relapsed/Refractory T-cell Lymphoma. Available online: https://clinicaltrials.gov/ct2/show/NCT03770000. Accessed 30 Apr 2022

  7. Compassionate Use Study of Tenalisib (RP6530). Available online: https://clinicaltrials.gov/ct2/show/NCT03711604. Accessed 30 Apr 2022

  8. Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M (2015) Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. Clin Lymphoma Myeloma Leuk 15(5):e83–e93. https://doi.org/10.1016/j.clml.2014.09.013

    Article  PubMed  Google Scholar 

  9. Kim YH, Bagot M, Pinter-Brown L et al (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial [published correction appears in Lancet Oncol. 2018 Nov;19(11):e581]. Lancet Oncol 19(9):1192–1204. https://doi.org/10.1016/S1470-2045(18)30379-6

  10. Beygi S, Duran GE, Fernandez-Pol S, Rook AH, Kim YH, Khodadoust MS (2022) Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma [published online ahead of print, 2022 Apr 18]. Blood blood.2021014468. https://doi.org/10.1182/blood.2021014468

  11. Hughes CF, Khot A, McCormack C et al (2015) Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125(1):71–81. https://doi.org/10.1182/blood-2014-07-588236

    Article  CAS  PubMed  Google Scholar 

  12. Talpur R, Thompson A, Gangar P, Duvic M (2014) Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14(4):297–304. https://doi.org/10.1016/j.clml.2014.01.010

    Article  PubMed  Google Scholar 

  13. Carlo-Stella C, Delarue R, Scarfo L et al (2020) A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. Clin Lymphoma Myeloma Leuk 20(2):78–86. https://doi.org/10.1016/j.clml.2019.10.013

    Article  PubMed  Google Scholar 

  14. Iyer SP, Huen A, Ferreri AJM et al (2018) Pooled safety analysis and efficacy of Tenalisib (RP6530), a PI3K δ/γ inhibitor in patients with relapsed/refractory lymphoid malignancies. Blood 132:2925. https://doi.org/10.1182/blood-2018-99-112757

    Article  Google Scholar 

  15. Iyer S, Huen A, Ai W et al (2021) Safety and efficacy of tenalisib given in combination with Romidepsin in patients with relapsed/refractory T-Cell Lymphoma: Final results from a phase I/II open label multi-center study. Blood (ASH Annual Meeting Abstracts)

  16. Kaneda MM, Messer KS, Ralainirina N et al (2016) PI3Kγ is a molecular switch that controls immune suppression. Nature 539(7629):437–442. https://doi.org/10.1038/nature19834

  17. Lewis J, Girardi M, Vakkalanka S, Viswanadha S, Bertoni F (2013) RP6530, a dual PI3Kδ/γ inhibitor, attenutates AKT phosphorylation and induces apoptosis in primary cutaneous T cell lymphoma (CTCL) cells. Blood 22:4418. https://doi.org/10.1182/blood.V122.21.4418.4418

    Article  Google Scholar 

Download references

Acknowledgements

AOH conceptualized the paper. SPI, MD, and AOH participated in patient care. CNN wrote the original manuscript draft. CNN, SPI, MD, PJB, AN, KVR, and AOH reviewed and edited the manuscript.

Funding

This work was supported by Rhizen Pharmaceuticals AG, Basel, Switzerland.

Author information

Authors and Affiliations

  1. Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Christopher N. Nguyen, Madeleine Duvic & Auris O. Huen

  2. Department of Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Swaminathan P. Iyer

  3. Rhizen Pharmaceuticals AG, Basel, Switzerland

    Prajak J. Barde, Ajit Nair & Kasi Viswanath Routhu

Authors
  1. Christopher N. Nguyen
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Swaminathan P. Iyer
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Madeleine Duvic
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Prajak J. Barde
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Ajit Nair
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Kasi Viswanath Routhu
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Auris O. Huen
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Christopher N. Nguyen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflicts of interest

The authors report there are no competing interests to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nguyen, C.N., Iyer, S.P., Duvic, M. et al. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome. Invest New Drugs 41, 350–355 (2023). https://doi.org/10.1007/s10637-022-01315-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-022-01315-6

Keywords